Synergy between scientific advancement and technological innovation, illustrated by a mechanism-based model characterizing sodium-glucose cotransporter-2 inhibition.
Advances in experimental medicine and technological innovation during the past century have brought tremendous progress in modern medicine and generated an ever-increasing amount of data from bench and bedside. The desire to extend scientific knowledge motivates effective data integration. Technological innovation makes this possible, which in turn accelerates the advancement in science. This mutually beneficial interaction is illustrated by the development of an expanded mechanism-based model for understanding a novel mechanism, sodium-glucose cotransporter-2 SGLT2 inhibition for potential treatment of type 2 diabetes mellitus.
Zhang
Liping
L
Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb, Princeton, New Jersey, USA. liping.zhang3@bms.com
Ng
Chee M
CM
List
James F
JF
Pfister
Marc
M
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008954:Models, Biological; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013678:Technology, Pharmaceutical / Q000379:methods
D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors